Beijing Konruns Pharmaceutical Co Ltd

Konruns Pharmaceutical announced on October 9 that as of September 30, 2026, the company had repurchased 2 million shares, accounting for 1.24% of total share capital, with a repurchase amount of 78.43 million yuan and a repurchase price range of 28.36 yuan to 51.4 yuan per share. In the first half of 2026, Konruns Pharmaceutical achieved revenue of 463 million yuan and net profit attributable to the parent of 95.72 million yuan.

Konruns Pharmaceutical released its 2026 interim report, with total operating revenue of 463 million yuan and net profit attributable to the parent company of 95.7226 million yuan. Net cash inflow from operating activities was 4.5587 million yuan, the asset-liability ratio was 15.68%, gross margin was 89.81%, ROE was 3.01%, and diluted earnings per share was 0.61 yuan. The number of shareholders was 15,300, and the top ten shareholders held 54.42% of total share capital.

Konruns Pharmaceutical released its 2026 semi-annual report, achieving net profit attributable to shareholders of approximately 95.7226 million yuan in the first half, up 5.14% year on year. The company achieved operating revenue of approximately 463 million yuan in the same period, up 0.42% year on year. During the reporting period, research and development investment was approximately 64.9779 million yuan, up 29.03% year on year, accounting for 14.04% of operating revenue, with the development progress of core pipeline drug candidates continuing to advance rapidly. Konruns Pharmaceutical focuses on the research and development, production, and sales of innovative drugs.